Notice Regarding the Launch of "StemEdit," a Clinical-Grade Gene Editing Service

January 27, 2026

REPROCELL Inc. (the “Company”) hereby announces that it has launched “StemEdit,” a gene editing service for clinical use. StemEdit is a gene editing service suitable for clinical applications achieved by combining the AI-designed genome editing system “OpenCRISPR-1™”—licensed from Profluent Bio, Inc. (headquartered in California, USA)—with the Company’s proprietary clinical-grade gene editing technologies and the expertise it has accumulated over many years.
By combining the Company's clinical-grade iPS cells, which comply with regulations in Japan, the United States, and Europe, with “OpenCRISPR-1™,” this service provides seamless support for the entire process from the research stage to the clinical application of gene-edited clinical-grade iPS cells.

Features of This Service and Product
Next-Generation Genome Editing Technology via AI Design: “OpenCRISPR-1™” is an artificial protein-designed genome editing system developed by Profluent Bio using large language models (LLMs). The high editing efficiency and reduced off-target effects of this system enable the efficient production of universal donor iPS cells. This is expected to contribute to reducing the risk of immune rejection in transplantation medicine.

Suitability for Clinical Application: Utilizing a GMP-compliant workflow and clinical-grade iPS cell seed clones, the service supports a smooth transition from the research stage to clinical application and commercial production.

Reduction of Barriers to Commercialization: By providing an alternative to conventional gene editing technologies that often involve complex licensing issues, this service contributes to resolving intellectual property and commercial challenges in the development of cell therapies.

While the impact of this matter on the Company's business performance for the current period is expected to be minor at this time, the Company will promptly disclose any information should it be determined that a significant impact on performance will occur due to future sales progress or other factors.

About Profluent Bio

Profluent Bio is a biotechnology company that develops “OpenCRISPR-1™,” an AI-designed genome editing system. The company leverages large language models trained on massive biological sequence

data to enable the design of high-performance proteins that transcend the constraints of natural evolution.

Glossary

Off-target effects: A phenomenon in genome editing where DNA sequences different from the intended target are mistakenly cleaved or edited. Because this can cause unexpected side effects, reducing off-target effects is an extremely important metric for ensuring the safety of gene and cell therapies.

Universal donor iPS cells: iPS cells that have been modified using gene editing technology to alter factors responsible for immune rejection (such as HLA), making them transplantable regardless of immune type compatibility. Since individual cell production for each patient is not required, large-scale pre-manufacturing and stockpiling are possible, leading to significant reductions in manufacturing costs and the establishment of rapid delivery systems.